University of Maryland/Greenebaum Cancer Center

University of Maryland/Greenebaum Cancer Center is a medical facility located in Baltimore, Maryland. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Leukemia, Lymphoma and other specialties. University of Maryland/Greenebaum Cancer Center is involved with conducting 671 clinical trials across 536 conditions. There are 30 research doctors associated with this hospital, such as Ranee Mehra, MD, Mark Mishra, MD, Teresa A. York, and Katherine Scilla, MD.

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, situated at 22 S Greene St, Baltimore, MD 21201, is a key component of the University of Maryland Medical System. It provides outpatient care in the Roslyn and Leonard Stoler Pavilion, conveniently located inside the main hospital lobby. For new patient appointments, contact 410-328-7904 or 1-800-888-8823.

**University of Maryland/Greenebaum Cancer Center Financial and Insurance Assistance:** - For financial assistance, visit the University of Maryland Faculty Physicians, Inc. financial assistance page. - For insurance inquiries, contact the University of Maryland Medical System's Patient Assistance Line at 410-328-7609. - For assistance with insurance and billing questions, call the Health Center staff at 301-314-8147.

The University of Maryland/Greenebaum Cancer Center accepts a wide range of insurance plans, including commercial health insurance, Medicaid, and Medicare. It is in network with Aetna, Blue Cross Blue Shield (excluding Omnia Silver), Carefirst, United Health Care, and Cigna's PPO and Open Access Plus products. Patients are encouraged to verify coverage with their insurance company before visiting, as certain services like x-ray and in-house laboratory services may not be covered under specific plans such as Maryland Medicaid and Carefirst Blue Choice.

The University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCCC) is nationally recognized for its excellence in cancer treatment and research, holding a "comprehensive" designation from the National Cancer Institute (NCI). This places UMGCCC among the elite cancer centers in the United States, focusing on hormone responsive cancers, tumor immunology and immunotherapy, molecular and structural biology, and population science. Additionally, it is recognized as a Center of Excellence by various health insurance companies and national transplant networks for meeting or exceeding quality of care and patient survival benchmarks.